Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
Christine Dierks,Jochen Seufert,Konrad Aumann,Juri Ruf,Claudius Klein,Selina Kiefer,Michael Rassner,Melanie Boerries,Andreas Zielke,Paul la Rosee,Philipp Tobias Meyer,Matthias Kroiss,Christian Weißenberger,Tilmann Schumacher,Patrick Metzger,Harald Weiss,Constantin Smaxwil,Katharina Laubner,Justus Duyster,Nikolas von Bubnoff,Cornelius Miething,Oliver Thomusch
DOI: https://doi.org/10.1089/thy.2020.0322
IF: 6.506
2021-07-01
Thyroid
Abstract:Background: Anaplastic thyroid carcinoma (ATC) and metastasized poorly differentiated thyroid carcinomas (PDTC) are rare aggressive malignancies with poor overall survival despite extensive multimodal therapy. Tumors are highly proliferative, with frequently increased tumor mutational burden (TMB) compared to differentiated thyroid carcinomas, and elevated PD-L1 levels. These tumor properties implicate responsiveness to anti-angiogeneic and anti-proliferative multikinase inhibitors like lenvatinib, and immune checkpoint inhibitors like pembrolizumab. Patients and methods: In a retrospective study, we analyzed six patients with metastasized ATC and two patients with PDTC, who received a combination therapy of lenvatinib and pembrolizumab. Lenvatinib was started at 14 to 24 mg daily, and combined with pembrolizumab at a fixed dose of 200 mg every three weeks. Maximum treatment duration with this combination was 40 months and 3/6 ATC patients are still on therapy. Patient tumors were characterized by whole exome sequencing (WES) and PD-L1 expression levels (Tumor Proportion Score, TPS 1-90%). Results: Best overall response (BOR) within ATCs was 66% complete remissions (4/6 CR), 16% stable disease (1/6 SD) and 16% progressive disease (1/6 PD). BOR in PDTCs was partial remission (PR 2/2). Median progression free survival (PFS) is 17.75 months for all patients, and 16.5 months for ATCs, with treatment durations ranging from 1 to 40 months (1, 4, 11, 15, 19, 25, 27, 40 months). Grade III/IV toxicities developed in 4/8 patients, requiring dose reduction/discontinuation of lenvatinib. Median overall survival (OS) is 18.5 months, with 3 ATC patients being still alive without relapse (40, 27 and 19 months) despite metastatic disease at treatment start (UICC Stage 4C). All patients with long-term (> 2 years) or complete responses had either increased TMB or a PD-L1 TPS > 50%. Conclusion: Our results implicate that the combination of lenvatinib and pembrolizumab might be safe and effective in patients with ATC/PDTC including complete and long-term remissions. The combination treatment is now systematically examined in a phase II clinical trial (Anaplastic Thyroid Carcinoma Lenvatinib Pembrolizumab - ATLEP) in ATC/PDTC patients.
endocrinology & metabolism